



PCCP

**R vs. S Fluoroproline ring substitution: trans/cis effects on the formation of b<sub>2</sub> ions in gas-phase peptide fragmentation**

Journal:	<i>Physical Chemistry Chemical Physics</i>
Manuscript ID	CP-ART-08-2015-005155.R1
Article Type:	Paper
Date Submitted by the Author:	16-Nov-2015
Complete List of Authors:	Bernier, Matthew; Georgia Tech, Chemistry and Biochemistry Chamot-Rooke, Julia; CNRS Institut Pasteur, Structural Biology and Chemistry Dept Wysocki, Vicki; Ohio State University, Chemistry and Biochemistry

SCHOLARONE™  
Manuscripts

**R vs. S Fluoroproline ring substitution: *trans/cis* effects on the formation of  $b_2$  ions in gas-phase peptide fragmentation**

Matthew Bernier<sup>1</sup>, Julia Chamot-Rooke<sup>2</sup>, Vicki Wysocki<sup>1\*</sup>

Permanent Address: <sup>1</sup>Ohio State University, Columbus, Ohio; <sup>2</sup>Institut Pasteur, Paris, France.


**Keywords:** Collision induced dissociation, fluoroproline, peptide, prolyl ring substitution,  $b_2$  ion

**Abstract:**

The  $b_2$  structures of model systems Xxx-Flp-Ala (Flp = 4R-fluoroproline) and Xxx-flp-Ala (flp = 4S-fluoroproline) (where Xxx is Valine or Tyrosine) were studied by action IRMPD spectroscopy to test whether proline ring substitutions could influence the conformation of the precursor ion in such a way as to influence the  $b_2$  fragment ion structure formed by collision induced dissociation. Vibrational spectra of the  $b_2$  ions of Val-Flp and Val-flp exhibit highly intense bands at  $\sim 1970\text{ cm}^{-1}$ , revealing that the dominant ion in each case is an oxazolone. The major difference between the spectra of  $b_2$  ions for R vs. S fluoroproline is a collection of peaks at 1690 and 1750  $\text{cm}^{-1}$ , characteristic of a diketopiperazine structure, which were only present in the 4S-fluoroproline (flp) cases. This suggests only one  $b_2$  ion structure (oxazolone) is being formed for Flp-containing peptides, whereas flp-containing peptides produce a mixture of a dominant oxazolone with a lower population of diketopiperazine. In solution, Flp is known to possess a higher *trans* percentage in the N-terminally adjacent peptide bond, with flp inducing a greater proportion of the *cis* conformation. The diketopiperazine formation observed here correlates directly with the  $K_{trans/cis}$  trend shown in solution in previous studies, highlighting that the *trans/cis* isomerization likelihood for proline residues modified in the 4<sup>th</sup> position is retained in the gas-phase.

**Introduction:**

In the field of peptide fragmentation, the b ion structures formed *via* collision induced dissociation (CID) have been well characterized for several sequences. CID induces fragmentation along the peptide backbone at the peptide bond, and when this bond is cleaved charge can be retained either C-terminally to the dissociated peptide bond to form a y-ion or N-terminally of this bond to form a b-ion. While y-ions are truncated peptides, b-ions must adopt variable structures to adapt to a C-terminus without a hydroxyl group. In the case of the b<sub>2</sub> ion, cyclization allows formation of either a five-membered oxazolone ring, in which the peptide bond retains its *trans* conformation, or a six-membered head-to-tail cyclized diketopiperazine structure (Scheme 1). To form the diketopiperazine, the peptide bond must undergo a *trans/cis* isomerization and, despite calculations that show that the diketopiperazine is typically the more stable ion, the formation of the kinetically-favored oxazolone fragment is more frequently observed. [1] This is believed to be at least in part due to the unfavorable *cis* conformation, but has also been proposed to result from the relative barriers of ring closure between oxazolone and diketopiperazine. [2]



Scheme 1: Depiction of the formation of oxazolone and diketopiperazine structures for the  $b_2$  ion. The oxazolone  $b_2$  ions retain the *trans* amide bond conformation of the original peptide precursor while the diketopiperazine  $b_2$  ions must form via a *cis* amide bond. [3]

The amino acid proline favors the formation of the *cis* peptide bond more than any other natural amino acid. [4, 5] On average for protein amino acid residues, the barrier to *trans/cis* isomerization of the peptide bond adjacent to the N-terminus is approximately 20 kcal/mol, while for proline, this barrier is only 13 kcal/mol. [6] Additionally, the relative energies between the *trans* and *cis* isomers is about 2 kcal/mol less for proline in comparison to other residues. The lower barrier to isomerization allows b ions with a proline residue to form the diketopiperazine with greater frequency as can be observed in previous work. Gucinski *et al.* observed that the b ion structure of Val-Pro, Ala-Pro, and Ile-Pro are all mixtures of oxazolone and diketopiperazine and His-Pro is exclusively diketopiperazine. [7, 8] It was concluded in that work that the *trans/cis* isomerization barrier was an influential factor in the formation of the diketopiperazine for these systems. Furthermore, the exclusive diketopiperazine for His-Pro was

determined to be a result of both the basic His residue in the first position and the second position proline contributing to *cis* stability of the peptide.

The effect of substitution of the prolyl ring on *trans/cis* propensity has been examined predominantly in the solution-phase. For example, it is well known that collagen contains 4-hydroxyproline (Hyp) and, significantly, this amino acid modification in the repeating collagen unit provides stability to the collagen triple helix. Raines and coworkers have shown that inserting other substituents (i.e., fluorine and methyl) onto the prolyl rings in the Pro-Hyp-Gly motif can increase the melting temperature of the construct by over 20 °C compared to standard collagen. [9, 10] Further research by Raines and coworkers has also considered the isolated effects of proline substitution on *trans/cis* isomerization. In the case of a single acetylated and O-methylated (Ac-Xxx-OMe) form where Xxx is a substituted Pro, the  $K_{trans/cis}$  value of the acetyl-Xxx peptide bond was shown to change significantly with different substituents placed in the *R* or *S* position. Using 1-D proton NMR, the  $K_{trans/cis}$  of Pro was found to be 4.6. This ratio increased to 6.7 when a fluorine substituent at the 4-position was in the *R* configuration and decreased to 2.5 with fluorine in the *S* configuration.

The *trans/cis* character of each prolyl substitution was suggested to be directly influenced by the puckering of the prolyl ring. When in the *S* position, H, OH, or F puckers the ring toward the adjacent peptide bond to produce the  $C^\gamma$ -endo conformation. In the *trans* position, OH or F causes the ring to pucker away from the peptide bond into the  $C^\gamma$ -exo conformation. [11-14] This effect is represented in Figure 1, highlighting the four peptides studied in this experiment. For Tyr-flp-Ala and Val-flp-Ala (Figure 1a and 1b), where fluorine is in the *S* position, the ring is puckered into the  $C^\gamma$ -endo conformation while for Tyr-Flp-Ala and Val-Flp-Ala (Figure 1c and 1d), the fluorine is in the *R* position and the prolyl ring is puckered downward into the  $C^\gamma$ -exo position. The relationship of ring pucker to *trans* isomer favorability has been explained by the gauche effect of the downwards  $C^\gamma$ -exo puckering producing a hydrogen bonding interaction between the carbonyl in the peptide bond N-terminally adjacent locking the *trans* conformation into place. Another study by Crestoni *et al.* showed that the ions of the *R* and *S* 4-hydroxyproline amino acid (Hyp and hyp) could be distinguished using gas-phase vibrational

spectroscopy, with a blue shift of the carbonyl stretching mode for the *S* configuration,[15] and more recently Flick *et. al.* were able to distinguish the same two via ion mobility of their sodium and lithium adducts. [16] Along with this discovery they also noted that the  $C^{\gamma}$  ring puckering followed the same trend as found for collagen in solution for these gas-phase molecules.




Figure 1: Model peptides studied here and their proposed ring puckering positions: **a)** Tyr-flp-Ala ( $C^{\gamma}$ -endo), **b)** Val-flp-Ala ( $C^{\gamma}$ -endo), **c)** Tyr-Flp-Ala ( $C^{\gamma}$ -exo), **d)** Val-Flp-Ala ( $C^{\gamma}$ -exo).

Here the model systems Tyr-flp-Ala, Tyr-Flp-Ala, Val-flp-Ala, and Val-Flp-Ala were studied, in order to test the effects of Flp and flp in the second position within a peptide. Tyr and Val were chosen as the first amino acids, as valine is known to produce a mixture of oxazolone and diketopiperazine structures in  $b_2$  ions and tyrosine was also studied as it offers a non-basic phenyl group with very different properties from the imidazole side chain of histidine, whose effects on b-ion formation result in an overwhelming proportion of diketopiperazine.[17] Furthermore, Tyr has previously been shown to influence *trans/cis* character when N-terminally adjacent to proline.[18] As peptide bond isomerization is necessary for producing the diketopiperazine, the *trans* to *cis* tendency of each fluoro substituted peptide may correlate with the proportions of oxazolone and diketopiperazine in each  $b_2$  ion population. We test here whether loss or enhancement of the diketopiperazine character for each substitution is indicative of the system's gas-phase peptide *trans/cis* bond preference. Identification of the  $b_2$  ion structures is

achieved *via* gas-phase action IRMPD spectroscopy, supported by theoretical calculations enabling chemical information about each fragment ion to be obtained. Additionally, MS<sup>3</sup> of the b<sub>2</sub> ions was performed to determine how the *R* to *S* change of the fluorine on the prolyl ring influences the overall stability of the b<sub>2</sub> ion generated in each case.

### Experimental:

All peptides were synthesized using standard Fmoc-solid phase synthesis described in detail elsewhere.[19] Substituted Fmoc-protected 4*R*-Fluoroproline (Flp) and 4*S*-fluoroproline (flp) were purchased from BAchem while all other amino acids and synthesis reagents were purchased from EMD Biosciences, unless otherwise stated. Following cleavage from the resin, the remaining peptide solution was purified using diethyl ether (Sigma-Aldrich, MO) and the peptides extracted from the ether into water. Peptide solutions for MS analysis were prepared by diluting approximately 1:100 into H<sub>2</sub>O: ACN with 0.1% formic acid to a final concentration of 10 to 50 μM. All solvents were purchased from Sigma-Aldrich and used without any further purification.

Action IRMPD was performed at the Centre Laser Infrarouge d'Orsay (CLIO) using a free electron laser set-up and a Bruker Esquire 3000<sup>+</sup> 3-D ion trap with an electrospray ionization source. Maitre, Ortega, and co-workers have described the process in detail.[20-22] Briefly, each precursor tripeptide was isolated in the ion trap and activated with in-trap CID to produce the b<sub>2</sub> ion. Subsequently, the trapped b<sub>2</sub> fragment ion was irradiated by the FEL at steps of 4 cm<sup>-1</sup> from 1000-2000 cm<sup>-1</sup>. The IRMPD spectra were produced by plotting the intensity of all fragments formed from the b<sub>2</sub> ion over the intensity of residual b<sub>2</sub> ion precursor at each wavenumber. The laser output consisted of macropulses of 9 μs each at a repetition rate of 25 Hz. These macropulses consist of approximately 600 micropulses at 0.5-3 ps spaced out at gaps of 16 ns. With laser powers of 0.5-1 W for each micropulse, the total amount of energy per pulse was found to be about 30-100 μJ depending on the exact wavelength and power of the laser.

MS<sup>3</sup> CID spectra for each b<sub>2</sub> ion were produced on a Thermo Scientific Velos Pro dual linear ion trap at The Ohio State University. Each precursor tripeptide was isolated in the low pressure cell and dissociated in the high pressure cell via collision induced dissociation. A collision energy of 20-23% (normalized) was used to fragment each precursor tripeptide and the b<sub>2</sub> ion formed was subsequently dissociated via CID at 23-30% normalized collision energy.

Theoretical b<sub>2</sub> ion structures and full tripeptide precursors were calculated using hybrid density functional theory at the B3LYP/6-311+G\*\* basis set. A conformational search of possible structures was produced using torsional sampling of the candidate structures using the Monte Carlo Multiple Minimum (MCM) with energy optimization *via* the Merck Molecular Force Field (MMFF).[23] From the list of generated structures, the 30-50 most stable unique structures of each sequence were submitted to Gaussian 09 for both optimization and frequency calculations.[24] The lowest energy structure for each set was found to be on average 0.5-1.5 kcal/mol lower than the next lowest structure and 7-12 kcal/mol lower than the most unstable of each unique structure found. The frequencies of these structures were scaled at 0.975 and used for comparison to the experimental IRMPD spectra produced at CLIO with artificial peak widths of 10 cm<sup>-1</sup> applied.

## Results and Discussion:

### *Action IRMPD Spectra:*

A collection of the b<sub>2</sub> ion experimental action IRMPD (blue traces) and the corresponding theoretical spectra of lowest energy calculated diketopiperazine and oxazolone structures (red traces) is shown in Figure 2, with Tyr-flp in Figure 2a, Tyr-Flp in 2b, Val-flp in 2c, and Val-Flp in 2d. All four b<sub>2</sub> ions show stretches in the 1950 cm<sup>-1</sup> region and a broad band within the region between 1580 and 1620 cm<sup>-1</sup>, suggesting the possibility of multiple overlapping peaks. The stretch at 1950 cm<sup>-1</sup> (see red shaded regions) is indicative of an oxazolone structure as it corresponds to the amide I carbonyl stretch observed for each theoretical oxazolone spectrum in red and is notably weak in Tyr-flp; the theoretical spectra of the oxazolone ions also show multiple bands in the region ~1600 cm<sup>-1</sup>, suggesting the broad feature



observed for Val-flp, Val-Flp, and Tyr-Flp in particular could be due to the oxazolone structure. For both Tyr-Flp (b) and Val-Flp (d), these two oxazolone band regions (1950 and 1600  $\text{cm}^{-1}$ ) are the prominent features of the spectra above 1400  $\text{cm}^{-1}$  suggesting that the dominant structure for the two Flp containing  $b_2$  ions is the oxazolone.

For both Tyr-flp and Val-flp, there are a unique set of bands at approximately 1690 and 1750  $\text{cm}^{-1}$  that make up a major proportion of the fragmentation efficiency signal (see blue shaded regions). For Val-flp, there is a clear peak at 1760  $\text{cm}^{-1}$  and a smaller peak at 1690  $\text{cm}^{-1}$  adjacent to a broad feature at  $\sim 1600 \text{ cm}^{-1}$ . For the calculated diketopiperazine of Tyr-flp, there are strong bands at 1750 and 1670  $\text{cm}^{-1}$  with no similar broad feature at  $\sim 1600 \text{ cm}^{-1}$ . These bands correspond to the ring carbonyl stretching (1750  $\text{cm}^{-1}$ ) and the C=N in-ring stretching (1670  $\text{cm}^{-1}$ ) of the diketopiperazine. The carbonyl stretch is in excellent agreement with the experimental band at 1760  $\text{cm}^{-1}$  whereas the C=N stretch is slightly blue shifted in the action IRMPD spectrum. The shifting is even more pronounced for Val-flp, in that the lower diketopiperazine calculated “fingerprint” band at 1645  $\text{cm}^{-1}$  is about 40  $\text{cm}^{-1}$  red-shifted from the 1690  $\text{cm}^{-1}$  experimental peak. In examining the theoretical spectra of the higher energy diketopiperazines, no pair of diketopiperazine stretches was found from the list of computed structures to match completely the two experimental peaks at 1690 and 1750  $\text{cm}^{-1}$ .




Figure 2: Experimental IR spectra (blue) of  $b_2$  ions from a) Tyr-flp-Ala, b) Tyr-Flp-Ala, c) Val-flp-Ala, and d) Val-Flp-Ala compared to the theoretical diketopiperazine and oxazolone structures (red) of each. The relative energies of each pair of calculated structures as well as ball and stick models of each structure are shown in the insets of each calculated spectrum. The major stretching regions for the diketopiperazine and oxazolone are highlighted in blue and red boxes, respectively, for each  $b_2$  ion.

There are no readily observable peaks for the Tyr-Flp (Figure 2b) that match the diketopiperazine stretching region, though a tiny peak at  $\sim 1735$  cm<sup>-1</sup> may suggest a faint band in the Tyr-Flp case. In the case of Val-Flp, no discernible bands are present in the region between 1690 and 1750 cm<sup>-1</sup>. There is,

however, a small band at  $1650\text{ cm}^{-1}$  adjacent and contributing to the broad feature centered at about  $1615\text{ cm}^{-1}$ . This  $1650\text{ cm}^{-1}$  band matches well with the C=N in-ring stretch of the calculated diketopiperazine, but the lack of a corresponding  $\sim 1700$  feature strongly suggests that this is an oxazolone band that corresponds to the minor  $1640\text{ cm}^{-1}$  band of the two oxazolone peaks at  $1590\text{ cm}^{-1}$  and  $1640\text{ cm}^{-1}$ .

From the action IRMPD spectra (summarized in Table 1), it is clear that there is little to no formation of diketopiperazine when substituting the 2<sup>nd</sup> position proline with a 4*R*-fluoroproline (Flp - high  $K_{\text{trans/cis}}$ ), but a greater prevalence of the diketopiperazine with the fluorine in the *S* position (flp - low  $K_{\text{trans/cis}}$ ). The *S*-substitution retains the oxazolone bands in Tyr-flp (Figure 2a), as shown by the presence of a weak amide I carbonyl vibrational stretch, yet the diketopiperazine structure becomes the dominant species. This is in contrast to the Val-*Xxx* systems (Figure 2c and 2d), where both substitutions retain large oxazolone bands from  $1930\text{-}1950\text{ cm}^{-1}$  with the expected diketopiperazine peaks at  $1700$  and  $1760\text{ cm}^{-1}$  observed only in the Val-flp case. Thus while the *S*-fluoro substitution promotes formation of the diketopiperazine structure for both Tyr-flp and Val-flp, in the case of Val-flp the results suggest that a substantial proportion of ions that retain a *trans* peptide bond and formation of the oxazolone structure. Additionally, it should be noted that for all four  $b_2$  ions, the diketopiperazine was found to be the lowest energy structure (inset of Figure 2). Each oxazolone was at least  $11\text{ kcal/mol}$  higher in energy than the diketopiperazine with of the oxazolone of Tyr-Flp  $21\text{ kcal/mol}$  higher in energy than the diketopiperazine. Because Tyr-Flp was found to show only oxazolone stretches in its IRMPD spectrum this suggests that the absolute energy of the resulting  $b_2$  ion is not a factor in its formation consistent with the general understanding that fragmentation in MS/MS is kinetically driven.

b <sub>2</sub> Identity	Oxazolone Stretch	Diketopiperazine Stretches		Major Structure
	Amide 1 C=O	Ring C=O	In-Ring C=N	
Tyr-flp	Minor @ 1925 cm <sup>-1</sup> (13%)	Major @ 1760 cm <sup>-1</sup> (100%)	Major @ 1695 cm <sup>-1</sup> (75%)	Diketo
Tyr-Flp	Major @ 1925/1890 cm <sup>-1</sup> (100%)	Minor @ 1750 cm <sup>-1</sup> (10%)	Not Observed	Oxaz
Val-flp	Major @ 1905 cm <sup>-1</sup> (100%)	Major @ 1740 cm <sup>-1</sup> (40%)	Moderate @ 1690 cm <sup>-1</sup> (20%)	Diketo/Oxaz
Val-Flp	Major @ 1920 cm <sup>-1</sup> (100%)	Not Observed	Not Observed	Oxaz

Table 1: Major and minor stretches of each b<sub>2</sub> ion and the percentage of each relative to the most intense stretch in the fingerprinting region. The final column suggests the major structure based on the contributions of each identifying stretch.

### MS<sup>3</sup> b<sub>2</sub> ion fragmentation:

Figure 3 shows the b<sub>2</sub> MS<sup>3</sup> CID spectra (MH<sup>+</sup>→b<sub>2</sub>→fragments) of Val-flp-Ala (Figure 3a) and Val-Flp-Ala (Figure 3b) produced in a Thermo Scientific Velos Pro dual cell linear ion trap. Both spectra were collected using the same 23% relative CID collision energy for the precursor and b<sub>2</sub> ion. The top spectrum, Val-flp-Ala contains a residual precursor b<sub>2</sub> ion at approximately 30% normalized CID intensity and the a<sub>2</sub> ion (loss of CO) as the most intense peak. The HF loss from the a<sub>2</sub> and the [HF+CO] loss from a<sub>2</sub> also produce dominant peaks at this fragmentation energy. The b<sub>2</sub> ion undergoes NH<sub>3</sub> loss, HF loss, an imine loss to produce *m/z* 144, as well as combinations of these losses (a<sub>2</sub>-HF-CO-NH<sub>3</sub> and b<sub>2</sub>-imine-CO). Additionally, both the flp and Val iminium ion fragments are observed at *m/z* 88 and 72, respectively. In the case of the Val-Flp b<sub>2</sub> ion, significantly fewer high intensity fragments are observed. Again, the most intense peak in the spectrum is the a<sub>2</sub> ion at *m/z* 187, followed by the imine loss fragment. Other fragments present include the b<sub>2</sub>-H<sub>2</sub>O, a peak at *m/z* 171 believed to be a CO<sub>2</sub> loss from the b<sub>2</sub>, a CO loss from the b<sub>2</sub>-imine fragment, and the two peptide iminium fragments Val<sub>imm</sub> and Flp<sub>imm</sub>. Significantly, for the Val-Flp b<sub>2</sub> ion, no peak of reasonable intensity which corresponds to an HF loss is observed. This may be directly due to the C<sup>γ</sup>-exo ring conformation of the Val-Flp b<sub>2</sub> ion, in which the substituent is positioned in the proline ring such that it is inaccessible to any other functional groups within the small, inflexible fragment ion. Conversely, the C<sup>γ</sup>-endo conformation of the Val-flp b<sub>2</sub> ion makes it readily accessible to H-bonding with the other functional groups, allowing many possible

fluorine interactions to occur resulting in HF loss, as observed ( $b_2$ -HF,  $a_2$ -HF,  $a_2$ -HF-CO,  $a_2$ -HF-CO-NH<sub>3</sub>).




Figure 3: MS<sup>3</sup> of b<sub>2</sub> ions of **a)** Val-flp-Ala and **b)** Val-Flp-Ala performed on a Velos Pro linear ion trap. Precursor tripeptides were isolated and fragmented at 23% CID collision energy followed by isolation and fragmentation of each b<sub>2</sub> at m/z 215 at the same collision energy. The -Val<sub>imi</sub> label indicates the loss of the Valine neutral imine while Val<sub>imm</sub>, flp<sub>imm</sub>, and Flp<sub>imm</sub> labels indicate the iminium (immonium) ions of Valine, *S*-fluoroproline, and *R*-Fluoroproline, respectively.

Figure 4 presents the MS<sup>3</sup> spectral comparison for the Tyr-flp and Try-Flp b<sub>2</sub> ions. The IRMPD spectra above showed diketopiperazine dominated clearly for Tyr-flp while only oxazolone was readily observed for Tyr-Flp, which justifies the sharp differences in MS<sup>3</sup> of the Tyr-flp and Tyr-Flp b<sub>2</sub> ions. A distinct feature of the Tyr-flp b<sub>2</sub> ion is that its most intense fragment is the Tyr iminium ion rather than the

$a_2$  as is the case for Tyr-Flp, Val-flp, and Val-flp. Because it is most facile to form the  $a_2$  through the oxazolone structure *via* a carbonyl loss, [25, 26] the fact that it is the least intense for the Tyr-flp  $b_2$  correlates with the action IRMPD results in which the oxazolone band stretches were the least intense for Tyr-flp.




Figure 4:  $MS^3$  of  $b_2$  ions of a) Tyr-flp-Ala and b) Tyr-Flp-Ala performed on a Velos Pro linear ion trap. Precursor tripeptides were isolated and fragmented at 20% HCD collision energy followed by isolation and fragmentation of each  $b_2$  ion at  $m/z$  279 with 25% CID collision energy. The  $-Tyr_{imi}$ ,  $-flp_{imi}$ , and  $-Flp_{imi}$  labels indicate losses of the Tyrosine, *S*-fluoroproline, and *R*-Fluoroproline imines while  $Tyr_{imm}$ ,  $flp_{imm}$ , and  $Flp_{imm}$  labels indicate the iminium ions of Tyrosine, *S*-fluoroproline, and *R*-Fluoroproline, respectively.

Significantly, it is clear that there is more residual  $b_2$  in the spectra of Val-flp and Tyr-flp than the corresponding Flp-containing ion precursors, where the  $b_2$  ion intensity has almost disappeared. This suggests that the *S* position fluorine of flp ( $C^{\gamma}$ -endo) is adding stability to the  $b_2$  ion compared to *R* position fluorine of Flp ( $C^{\gamma}$ -exo). It may also be that the ring puckering is retained in the oxazolone structure and is contributing to the very different spectra corresponding to the two differently substituted prolyl ring residues. The stability of these fragment ions could be in part due to the ability of the fluorine substituent to participate in further fragmentation pathways of the molecule, making the inherent stability of the fragments dependent on the stereochemistry of the ring substituents. This explains why there is such a large difference in remaining precursor between the Val-Flp and Val-flp  $b_2$  ions at the exact same  $MS^3$  fragmentation energy. Despite the fact that the  $b_2$  ion appears to be more stable for Val-flp there are, however, also a significantly greater number of different fragments for this  $b_2$  ion. Interestingly, this is less of a feature in the tyrosine dissociation comparison (Figure 4), where the two precursors are both almost completely gone.

*Comparison to solution phase trends via gas phase theoretical optimization:*

The experimental action IRMPD and  $MS^3$  spectra shown above define a clear trend for oxazolone/diketopiperazine ratios for *S*-substituted flp that agree with the  $K_{trans/cis}$  trend found by Shoulders *et al.* using solution-phase 1-D proton NMR.[9] This trend is that for the *S*-substituted flp second position tripeptides of Tyr-flp-Ala and Val-flp-Ala the *cis* peptide bond is more likely in solution and the experiments above follow that trend with the diketopiperazine present in greater proportions for these substitutions. As the  $K_{trans/cis}$  trend observed previously in solution correlates with the peptide bond conformation necessary for diketopiperazine formation, it is desirable to also determine whether the prolyl ring puckering observed in the solution-phase is preserved the gas-phase. Additionally, while no experimental data were collected for the precursor tripeptides, it is critical to determine their most likely structures *in silico* as the structure of each  $b_2$  ion is formed directly from its tripeptide precursor. The lowest energy N-protonated tripeptides (a) Tyr-flp-Ala, (b) Val-flp-Ala, (c) Tyr-Flp-Ala, and (d) Val-Flp-

Ala, calculated with DFT, are shown in Figure 5. As shown in the boxed region in Figure 5 on the prolyl ring section of the molecule, the fluorine substitution on the 4<sup>th</sup> position of the prolyl ring causes the ring to pucker towards the side on which the fluorine is added. This was observed previously by Crestoni *et al.* for Hyp and hyp *in silico* in addition to Panasik *et al.* in solution-phase studies of collagen and Ac-Xxx-OMe where Xxx = Pro, flp, Flp, hyp, or Hyp. [5, 15] For Tyr-flp-Ala and Val-flp-Ala in Figure 5a and 5c, the ring orients into a C-endo position and the fluorine is involved in a hydrogen bond with the 3<sup>rd</sup> amide nitrogen (alanine). For Tyr-Flp-Ala and Val-Flp-Ala, the ring orients itself into the C<sup>γ</sup>-exo conformation, away from the majority of the other functional groups. Likewise, it appears that the strain of this ring results in less hydrogen bonding for the N-terminus and an overall lack of stability for the tripeptide (3 kcal/mol higher in energy). Val-flp-Ala is approximately 2.6 kcal/mol lower in energy than Val-Flp-Ala and Tyr-flp-Ala is 2.4 kcal/mol lower than Tyr-Flp-Ala.






Figure 5: **a)** Tyr-flp-Ala, **b)** Tyr-Flp-Ala, **c)** Val-flp-Ala, and **d)** Val-Flp-Ala protonated tripeptide models calculated at the B3LYP/6-31+G\*\* with Gaussian 09, with fluorine indicated in gold. Using gas phase conditions the ring puckering of the *R* and *S* fluoroproline structures form the  $C^{\gamma}$ -endo and  $C^{\gamma}$ -exo conformations that are present in solution.[13] Prolyl rings for all fluoroprolines are boxed in black and are oriented to show a full side view to most clearly display the ring puckering.

Previous studies on the ring puckering of proline considered only whole peptides and not the fragments corresponding to the  $b_2$  ion, hence, Gaussian structures of the oxazolone and diketopiperazine fragments were also studied here to determine if ring puckering would be retained in their gas-phase formation. Figure 6 shows DFT optimized lowest energy structures of the oxazolones (Figure 6a-d) and diketopiperazines (Figure 6e-h) of Tyr-flp, Tyr-Flp, Val-flp and Val-Flp. As shown in the MS<sup>3</sup> data above, the *R* and *S* position of the fluoro-substitution has a large effect on not only the precursor peptide which forms the  $b_2$  but on the  $b_2$  ion itself. Here the theoretical structures show that the ring puckering is retained independent of whether the ion is oxazolone or diketopiperazine. Furthermore, the models containing flp in the second position explain the HF loss observed for Tyr-flp and Val-flp and the absence

of these fragments for the Flp analogues in  $MS^3$  experiments (Figure 3b and Figure 4b, respectively). For Flp containing oxazolone or diketopiperazine (Figure 6b, 6d, 6f, and 6h), no other functional group can participate in an internal reaction with the fluorine on the prolyl ring without a significant strain on the molecule, resulting in little to no reactivity of this substituent after formation of the  $b_2$  product ion. In contrast for flp (Figure 6a, c, e, and g), H-bonding to F is possible and allows for reactions resulting in the HF-loss, as seen in the flp-containing  $b_2$  ions above in the  $MS^3$  section (Figure 3 and 4). The theoretical calculations coupled with the data from the IRMPD and  $MS^3$  allows for a confirmation of not only the structural differences of the R/S prolyl substitutions, but also helps in elucidating the reasons for why those fragmentation and vibrational differences occur in the gas-phase.




Figure 6: Protonated oxazolone  $b_2$  models (top row) of **a)** Tyr-flp, **b)** Tyr-Flp, **c)** Val-flp, **d)** Val-Flp and their corresponding diketopiperazine  $b_2$  ion models directly below each oxazolone model (**e-h**) calculated at the B3LYP/6-311+G\*\* level with Gaussian 09 with prolyl rings boxed in black. For these two fragment structures, as with the tripeptide precursors, the ring pucker conformations of the R and S fluoroproline substitutions are retained.

*The influence of Histidine in the first position on  $b_2$  ions of His-Flp-Ala and His-flp-Ala*

A set of IRMPD and MS<sup>3</sup> data from the His-Flp-Ala and His-flp-Ala tripeptides was also run and is shown in the supplemental (Figure S1 and Figure S2). The identity of the  $b_2$  ions from this particular set was shown to be independent of the stereochemistry of the 4<sup>th</sup> position of the prolyl ring and both His-flp and His-Flp were clearly observed to be exclusively diketopiperazine. Additionally the fragments formed were the same for both His-Flp and His-flp with the exception of the HF loss, a sign of both  $b_2$  populations having the same structure. Previous work by Gucinski and coworkers has already confirmed the exclusivity of the diketopiperazine structure in His-Pro  $b_2$  ions and the supplemental data suggest that despite the ability of the fluoroproline to increase the  $K_{trans/cis}$  of the peptide bond this effect does not overcome the effect of the imidazole of the histidine on the resulting  $b$  ion structure.[17]

**Conclusions:**

The results above reveal that the 4-substitution of the prolyl ring in the second position of tripeptides has a significant effect on relative populations of diketopiperazine and oxazolone in  $b_2$  ion fragments. From action IRMPD spectra, distinct trends were found for Tyr and Val with Flp or flp in the second position. In the case of tyrosine in the first position (i.e. Tyr-Flp vs. Tyr-flp), there is a stark contrast in vibrational stretches with oxazolone the only structure observed for Tyr-Flp and the diketopiperazine the dominant structure for Tyr-flp, with only a minor abundance of oxazolone. With valine in the first position, the dominant structure remained the oxazolone in both cases but a diketopiperazine population was also present for Val-flp. The general trend here also carried over for the MS<sup>3</sup> spectra of each population of  $b_2$  ions. For Tyr-Flp and Tyr-flp, the differences in  $b_2$  activation, including both precursor abundances and fragment types, was considerable, implying different structures for the two populations. Again, the valine subset showed greater similarities between Flp and flp substitutions but with a significant difference in the ammonia loss and interestingly an HF loss, a trend thought to be a result of the configuration of the fluorine on the ring.

The ion structure dependence for valine and tyrosine in the first-position correlated extremely well to the  $K_{trans/cis}$  prevalence previously found in solution-phase studies of these prolyl substituted residues. From the data presented here, it seems apparent that the nature of the first peptide bond directly influences the formation of diketopiperazine in gas-phase fragmentation into  $b_2$  ions. Second position substitutions of flp and Flp produced a primarily *cis* or *trans*  $b_2$  ion matching those trends previously observed in solution. Additionally, the *R* and *S* fluoroproline substitutions caused different degrees of  $b_2$  precursor dissociation at the same collision energy. By moving the fluorine on the gamma carbon of the prolyl ring from the *S* to the *R* configuration there is a significant change to the both the stability of the  $b_2$  ion and identity of its subsequent  $MS^3$  fragments. The position of the fluoro substitution is also seen to directly influence the ring-puckering of both the gas-phase precursors and their  $b_2$  ions, whether oxazolone or diketopiperazine, which further supports the relationship of these peptide ions to the effects of prolyl ring substitution in solution-phase peptide chemistry.

**Acknowledgements:**

The authors would like to thank Vincent Steinmetz and Philippe Maitre at the Laboratoire de Chimie Physique in Orsay, France for use of and assistance with the CLIO experimental facilities. Additional thanks go to The Ohio State University and the Ohio Supercomputing Center.

**References:**

- [1] B. Balta, V. Aviyente, C. Lifshitz, *Journal of the American Society for Mass Spectrometry*, 14 (2003) 1192-1203.
- [2] C. Bleiholder, S. Suhai, A.G. Harrison, B. Paizs, *Journal of the American Society for Mass Spectrometry*, 22 (2011) 1032-1039.
- [3] B. Paizs, S. Suhai, *Mass Spectrometry Reviews*, 24 (2005) 508-548.
- [4] D. Pal, P. Chakrabarti, *Journal of Molecular Biology*, 294 (1999) 271-288.
- [5] N. Panasik, E.S. Eberhardt, A.S. Edison, D.R. Powell, R.T. Raines, *International Journal of Peptide and Protein Research*, 44 (1994) 262-269.
- [6] W.L. Jorgensen, J. Gao, *Journal of the American Chemical Society*, 110 (1988) 4212-4216.
- [7] A.C. Gucinski, J. Chamot-Rooke, V. Steinmetz, A. Somogyi, V.H. Wysocki, *Journal of Physical Chemistry A*, 117 (2013) 1291-1298.
- [8] L.L. Smith, K.A. Herrmann, V.H. Wysocki, *Journal of the American Society for Mass Spectrometry*, 17 (2006) 20-28.
- [9] M.D. Shoulders, J.A. Hodges, R.T. Raines, *Journal of the American Chemical Society*, 128 (2006) 8112-8113.
- [10] M.D. Shoulders, K.J. Kamer, R.T. Raines, *Bioorganic & Medicinal Chemistry Letters*, 19 (2009) 3859-3862.
- [11] Y.C. Chiang, Y.J. Lin, J.C. Horng, *Protein Science*, 18 (2009) 1967-1977.
- [12] M.D. Shoulders, K.A. Satyshur, K.T. Forest, R.T. Raines, *Proceedings of the National Academy of Sciences of the United States of America*, 107 (2010) 559-564.
- [13] W. Kim, K.I. Hardcastle, V.P. Conticello, *Angewandte Chemie-International Edition*, 45 (2006) 8141-8145.
- [14] K.L. Gorres, R. Edupuganti, G.R. Krow, R.T. Raines, *Biochemistry*, 47 (2008) 9447-9455.
- [15] M.E. Crestoni, B. Chiavarino, D. Scuderi, A. Di Marzio, S. Fornarini, *Journal of Physical Chemistry B*, 116 (2012) 8771-8779.
- [16] T.G. Flick, I.D.G. Campuzano, M.D. Bartberger, *Analytical Chemistry*, 87 (2015) 3300-3307.
- [17] A.C. Gucinski, J. Chamot-Rooke, E. Nicol, A. Somogyi, V.H. Wysocki, *Journal of Physical Chemistry A*, 116 (2012) 4296-4304.
- [18] K.M. Thomas, D. Naduthambi, N.J. Zondlo, *Journal of the American Chemical Society*, 128 (2006) 2216-2217.
- [19] E. Atherton, R.C. Sheppard, *Solid-Phase Peptide Synthesis: A Practical Approach*, Oxford University Press, Oxford, U.K., 1989.
- [20] J. Lemaire, P. Boissel, M. Heninger, G. Mauclaire, G. Bellec, H. Mestdagh, A. Simon, S.L. Caer, J.M. Ortega, F. Glotin, P. Maitre, *Physical Review Letters*, 89 (2002).
- [21] L. Mac Aleese, A. Simon, T.B. McMahon, J.M. Ortega, D. Scuderi, J. Lemaire, P. Maitre, *International Journal of Mass Spectrometry*, 249 (2006) 14-20.
- [22] P. Maitre, S. Le Caer, A. Simon, W. Jones, J. Lemaire, H.N. Mestdagh, M. Heninger, G. Mauclaire, P. Boissel, R. Prazeres, F. Glotin, J.M. Ortega, *Nuclear Instruments & Methods in Physics Research Section a-Accelerators Spectrometers Detectors and Associated Equipment*, 507 (2003) 541-546.
- [23] MacroModel, in, Schrödinger, LLC, New York, NY, 2012.
- [24] M.J.T. Frisch, G. W.; Schlegel, H. B.; Scuseria, G. E.; M.A.C. Robb, J. R.; Scalmani, G.; Barone, V.; Mennucci, G.A.N. B.; Petersson, H.; Caricato, M.; Li, X.; Hratchian, H., A.F.B. P.; Izmaylov, J.; Zheng, G.; Sonnenberg, J. L.; Hada, M.; M.T. Ehara, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, Y.K. T.; Honda, O.; Nakai, H.; Vreven, T.; Montgomery, J. A., Jr.; J.E.O. Peralta, F.; Bearpark, M.; Heyd, J. J.; Brothers, E.; Kudin, V.N.K. K. N.; Staroverov, R.; Normand, J.; Raghavachari, K.; A.B. Rendell, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, J.M.K. N.; Millam, M.; Knox, J. E.; Cross, J. B.; Bakken, V.; C.J. Adamo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; A.J.C. Austin, R.; Pomelli, C.; Ochterski, J. W.;

Martin, R. L.; K.Z. Morokuma, V. G.; Voth, G. A.; Salvador, P.; J.J.D. Dannenberg, S.; Daniels, A. D.; Farkas, O.; J.B.O. Foresman, J. V.; Cioslowski, J.; Fox, D. J., Gaussian 09, in, Wallingford, CT, 2009.

[25] T. Yalcin, C. Khouw, I.G. Csizmadia, M.R. Peterson, A.G. Harrison, *Journal of the American Society for Mass Spectrometry*, 6 (1995) 1165-1174.

[26] T. Yalcin, I.G. Csizmadia, M.R. Peterson, A.G. Harrison, *Journal of the American Society for Mass Spectrometry*, 7 (1996) 233-242.